Protocols
11 protocol(s) meet the specified criteria
Disease Site: Kidney
Protocol No.TitleStatus
A031203RANDOMIZED PHASE II STUDY COMPARING CABOZANTINIB (NSC #761968 AND IND #116059) WITH COMMERCIALLY SUPPLIED SUNITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMAOpen (affiliates only)
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid TumorsOpen
CALGB90601-CIRBA Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell CarcinomaOpen (affiliates only)
COGAREN03B2Renal Tumors Classification, Biology, and Banking Study Open
D6410C00001A Phase I, First-Time-in Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with Solid Tumor CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
WO39210A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following NephrectomyOpen